OXCT1: A Key Enzyme in Fatty Acid Metabolism (G5019)

Target Name: OXCT1

NCBI ID: G5019

OXCT1

OXCT1: A Key Enzyme in Fatty Acid Metabolism

OXCT1 (somatic-type succinyl-CoA:3-oxoacid CoA-transferase) is a protein that plays a crucial role in the metabolism of fatty acids in the body. It is a key enzyme in the tricarboxylic acid (TCA) cycle, which is a central metabolic pathway that generates energy in the form of ATP from the breakdown of fatty acids. OXCT1 is responsible for transferring the carbon dioxide from the TCA cycle to the coenzyme A (CoA) molecule, which is then used to synthesize amino acids.

The TCA cycle is a complex metabolic pathway that involves the breakdown of fatty acids, the production of aromatic amino acids, and the production of carbon dioxide. The OXCT1 enzyme is a key enzyme in this pathway, as it transfers the carbon dioxide from the TCA cycle to the CoA molecule.

One of the unique features of OXCT1 is its substrate specificity. It is specific for succinyl-CoA, which is a derivative of the amino acid leucine. This means that OXCT1 will only transfer the carbon dioxide from succinyl-CoA, and not from other amino acids.

In addition to its substrate specificity, OXCT1 has several other unique features that make it an interesting drug target. One of its unique functions is its role in the regulation of cellular metabolism. OXCT1 is involved in the breakdown of fatty acids, which is essential for the synthesis of energy in the form of ATP. Additionally, OXCT1 is involved in the regulation of cellular signaling pathways, including the TCA cycle.

Another feature of OXCT1 is its role in the development and progression of certain diseases. Research has shown that OXCT1 is involved in the development of certain diseases, including cancer, obesity, and neurodegenerative diseases. By targeting OXCT1 with drugs, researchers may be able to develop new treatments for these diseases.

In addition to its role in disease development, OXCT1 is also a potential drug target. Several studies have shown that OXCT1 is a potential drug target, with several potential drug candidates currently in development. These drugs may be used to treat a variety of conditions, including cancer, obesity, and neurodegenerative diseases.

Overall, OXCT1 is a protein that plays a crucial role in the metabolism of fatty acids. Its unique substrate specificity and role in the regulation of cellular metabolism and signaling pathways make it an interesting drug target. Additionally, its involvement in the development and progression of certain diseases makes it a potential therapy for a variety of conditions. Further research is needed to fully understand the role of OXCT1 in human metabolism and to develop new treatments for its associated diseases.

Protein Name: 3-oxoacid CoA-transferase 1

Functions: Key enzyme for ketone body catabolism. Catalyzes the first, rate-limiting step of ketone body utilization in extrahepatic tissues, by transferring coenzyme A (CoA) from a donor thiolester species (succinyl-CoA) to an acceptor carboxylate (acetoacetate), and produces acetoacetyl-CoA. Acetoacetyl-CoA is further metabolized by acetoacetyl-CoA thiolase into two acetyl-CoA molecules which enter the citric acid cycle for energy production (PubMed:10964512). Forms a dimeric enzyme where both of the subunits are able to form enzyme-CoA thiolester intermediates, but only one subunit is competent to transfer the CoA moiety to the acceptor carboxylate (3-oxo acid) and produce a new acyl-CoA. Formation of the enzyme-CoA intermediate proceeds via an unstable anhydride species formed between the carboxylate groups of the enzyme and substrate (By similarity)

The "OXCT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OXCT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets